<DOC>
	<DOCNO>NCT01033149</DOCNO>
	<brief_summary>The specific aim study evaluate efficacy , tolerability , safety N-acetylcysteine ( NAC ) treatment bulimia nervosa .</brief_summary>
	<brief_title>N-acetylcysteine Treatment Bulimia Nervosa</brief_title>
	<detailed_description />
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Bulimia Nervosa</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Men woman , age 18 65 . The patient population expect predominantly make woman base previous research . 2 . Patients meet DSMIVTR criterion BN least last 6 month . These criterion follow : A. Recurrent episodes binge eat . An episode binge eat characterize following : 1 . Eating , fixed period time , amount food definitely large people would eat similar circumstance . 2 . A sense lack control eat episode B. Recurrent inappropriate compensatory behavior prevent weight gain , : selfinduced vomit ; misuse laxatives ; diuretic ; medication ; fast ; excessive exercise . C. Bingepurge episodes occur least two time week last 3 month D. Self evaluation unduly influence body shape weight E. The disturbance occur exclusively episodes anorexia nervosa . 3 . Capacity consent study comply study procedure . Criteria exclusion study follow : 1 . Have current body mass index ( BMI ) &lt; 20kg/m2 . 2 . Women pregnant lactate woman childbearing potential take adequate contraceptive measure . 3 . Subjects display clinically significant suicidality homicidality . 4 . A current recent ( within 6 month start NAC ) DSMIVTR diagnosis substance abuse dependence . 5 . History personality disorder ( eg , schizotypal , borderline , antisocial ) might interfere assessment compliance study procedures 6 . Clinically unstable medical disease , include cardiovascular , hepatic , renal , gastrointestinal , pulmonary , metabolic , endocrine systemic disease could interfere diagnosis , assessment , treatment BN . Patients biochemically euthyroid prior enter study . 7 . DSMIVTR Anorexia nervosa 8 . Serum potassium ≤ 0.3mmol/L 9 . Myocardial infarction within six month 10 . Subjects take 200 /µg selenium per day , 500 IU Vitamin E /day 11 . Subjects know suspect clinically relevant systemic medical disorder , include asthma , bronchospasm , respiratory insufficiency . 12 . Subjects recently use medication ( &lt; 14 day ) felt hazardous take NAC ( e.g . carbamazepine , nitroglycerin ) . 13 . Subjects previously enrol study ; subject previously treat NAC ; subject receive experimental drug use experimental device within 30 day . Subjects take psychotropic medication allow study long dose medication stable 3 month study inclusion plan modify dose study duration . Similarly , subject evolve psychotherapy BN allow participate attendance ongoing least 3 month study entry . Subjects change dos medication start new therapy discontinue study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>